News & AnalysisCellares locks in $82m Series BCellares Corporation, a life sciences technology company, has secured $82 million in Series B funding.ByIris Dorbian5 May 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsTechnologyBriefs